Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. - Wikidata - awgldk - TriplyDB

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.

http://www.wikidata.org/entity/Q35784692

about

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis.GLP-1 response to sequential mixed meals: influence of insulin resistance.Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

P2860

Q26739999-D9A1E17C-B4F6-4CBE-A887-FC88884A6486 Q33656442-C360D7C2-70B2-44CC-AA35-D49470C9EE6E Q35748827-ED106950-2FED-4B4E-8F0C-9A72177C843E Q37470522-CEC51929-1F11-4B18-A981-40BFCE54A811 Q47223795-8671E16C-AF14-4FFB-A5AE-24F828210F0B Q47248842-9B11F956-DC45-4B39-BBC6-2D2B74EAF893 Q47621594-AFFD0604-24BD-4CB9-B08E-3D2C62E1AC06 Q48103910-57355FA5-E6FB-4D25-80D4-06B95989AAA7 Q48340758-BC941E50-C043-4D5F-A78D-3EAFE3E898B5 Q48488584-EA46A686-4EA1-43D3-AC71-96820592CAC5 Q51278208-11C79A42-08C0-4EF5-89FA-17ECF47D1E50

P2860

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.

http://www.wikidata.org/entity/Q35784692

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@ast

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@en

type

label

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@ast

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@en

prefLabel

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@ast

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@en

P1433

Q35784692-D6C72C57-9522-4424-86A7-FE66F0061C37

P1476

Q35784692-3284E89C-DAA3-422E-95B7-02036F9BFCC2

P2093

Q35784692-10F70C44-ADBE-43D8-A37F-742F3AC2A29B

Q35784692-300C2BFF-13FE-4C43-B77F-33A51BAA6E56

Q35784692-68EAEB6F-14C6-4403-89CE-2BB5AB61BBAF

Q35784692-6DF37E9D-7DFD-4B60-9101-F4216DE66FBA

Q35784692-B39043E6-505A-4B03-A509-119884330900

Q35784692-B40C83EC-12C0-410F-A571-74E793672A7A

Q35784692-C86F0AAE-9C2F-4F47-828C-4C4281BBC7D2

P2860

Q35784692-014DF618-4E0E-43F0-A7C5-0C66FA49BB3A

Q35784692-03E69B5C-EB40-4300-A64E-47F616094D6A

Q35784692-045C4B0C-0814-44AB-AFFA-C99933F6DC69

Q35784692-0FA75816-7D83-4D2B-9BFD-F14BC69ED282

Q35784692-10886ABE-24E6-42BC-94AC-5AE473988EC0

Q35784692-13120ADD-62BE-4E58-BABF-D07F03E623BB

Q35784692-1749A721-743D-4E80-9D88-16CA7103ED62

Q35784692-18583DC4-DC5D-45AA-8BDE-3D801DAA9B30

Q35784692-2F7D099A-E866-4476-93B7-AFB449D83735

Q35784692-308D531E-3414-43B8-B37D-B031E793E151

P2888

Q35784692-B284CE87-E8BA-454F-B154-86138F679A93

P304

Q35784692-6200B7AA-D540-4551-AD2E-5788D0197061

P31

Q35784692-0AA0D4F7-BBA0-4889-B80B-990A8C6F2824

Q35784692-28239f2b-6d77-4a1f-8cce-9cb8d4405824

P356

Q35784692-4C7BEC16-FDF1-44B8-A8A8-B023D0537A82

P407

Q35784692-671286FA-587A-4F05-B50D-AF1AF413FCA7

P478

Q35784692-AD88A074-EE78-4240-B28C-95A67962ED71

P577

Q35784692-CDC269F0-D3CB-422E-B0D6-B4B90B556087

P5875

Q35784692-23F865A4-1CE1-469E-851E-2FE8453B7E20

P6179

Q35784692-BA1B280B-F7BC-438B-83C9-79802DCB3E98

P698

Q35784692-D3A40B05-0CC5-40BE-AA09-E7FFF4E4FF95

P921

Q35784692-8C54BA03-5042-440F-90D8-3A95D46330D6

Q35784692-FBC3F9C5-CE0E-4E62-97D2-E9F0D5EDFB05

P932

Q35784692-B0E8BB54-7C99-419B-836A-9DAAD1944E52

P356

P1433

Scientific Reports

P1476

Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.

@en

P2093

Hetang Jia

http://www.w3.org/2001/XMLSchema#string

Liang Wang

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Song

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

Yiming Mu

http://www.w3.org/2001/XMLSchema#string

Yu Liu

http://www.w3.org/2001/XMLSchema#string

Yuebo Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Carotid intima-media thickness measurements: what defines an abnormality? A systematic review.

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus

Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

P2888

P304

10202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP10202

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279299289

http://www.w3.org/2001/XMLSchema#string

P6179

1039666689

http://www.w3.org/2001/XMLSchema#string

P698

26111974

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

type-2 diabetes

P932

4481643

http://www.w3.org/2001/XMLSchema#string